Plus Therapeutics launches CNSide diagnostic in Texas

Plus Therapeutics Inc. (NASDAQ: PSTV) announced its wholly-owned subsidiary CNSide Diagnostics will make its cerebrospinal fluid assay platform commercially available in Texas starting August 2025, according to a company statement.

The clinical-stage pharmaceutical company said it will initially focus on National Cancer Institute-designated cancer centers and large private healthcare systems. The targeted institutions include University of Texas-Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health, and Texas Oncology.

The CNSide platform is designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company said the diagnostic tool demonstrates 92% sensitivity and 95% specificity, compared to cerebrospinal fluid cytology, the current standard of care.

"The CNSide assay is an invaluable diagnostic tool, relevant in providing important guidance in monitoring patient disease progression and in helping define patient treatment," said Michael Youssef, M.D., Assistant Professor in the Department of Neurology and the Department of Hematology and Oncology at UT Southwestern Medical Center.

Plus Therapeutics stated that more than 11,000 CNSide tests have been performed at over 200 U.S. cancer institutions since 2020, influencing treatment decisions in over 90% of cases. The company plans to expand testing services and broaden regional availability over the next 12 months.

Leptomeningeal metastases affect approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, according to the company.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• Lazard Global Total Return fund declares $0.1534 monthly distribution